Catherine Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Catherine Yu has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Ina Geerts
Clinical and Experimental Endocrinology, KU Leuven, Leuven, Belgium
2 shared publications - Katrien Benhalima
Clinical and Experimental Endocrinology, KU Leuven, Leuven, Belgium
2 shared publications - Annouschka Laenen
Center of Biostatics and Statistical Bioinformatics, KU Leuven, Leuven, Belgium
1 shared publication - Arianne Sweeting
Department of Endocrinology, Royal Prince Alfred Hospital and Charles Perkins Centre, University of Sydney, Sydney, NSW 2050, Australia
1 shared publication - Astrid Morrens
Department of Endocrinology, ZAS Palfijn, 2170 Merksem, Belgium
1 shared publication - Chantal Mathieu
Clinical and Experimental Endocrinology, University Hospitals Leuven-KUL, Leuven, Belgium
1 shared publication
Latest Publications
- Open Access
- 29 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (19) , 7581
Continuous Glucose Monitoring for Women with Gestational Diabetes, CORDELIA: A Multicentric Randomized Controlled Trial, Methodology and Design
Background/Objectives: Gestational diabetes mellitus (GDM) is associated with increased short- and long-term risks for both mother and child. Screening and treatment between 24 and 30 weeks’ gestation reduces adverse pregnancy outcomes, while emerging evidence suggests that earlier diagnosis and treatment (<20 weeks’) in high-risk populations may further improve neonatal outcomes. Currently, self-monitoring of blood glucose (SMBG) remains the standard of care for management but provides only intermittent glycemic data and limited insight into overall glucose patterns. Real-time continuous glucose monitoring (rt-CGM) has transformed management in pregnancies complicated by type 1 diabetes but has shown conflicting results in GDM; it is thus unclear whether similar benefits may extend to women with GDM, including women with early GDM. Methods: The Continuous Glucose Monitoring for Women With Gestational Diabetes (CORDELIA) study is an ongoing, large, open-label, multicenter randomized controlled trial conducted across 14 centers in Belgium and two centers in Australia. Women diagnosed with GDM are randomized in a 1:1 ratio to either rt-CGM (intervention group) or standard care with SMBG (control group). Both women with early GDM diagnosed before 20 weeks’ gestation and those diagnosed between 24.0 and 29.6 weeks’ gestation are included. Participants attend the following visits: baseline visit at GDM diagnosis, an additional visit at 20.0–23.9 weeks’ (if early GDM), 31.0–33.6 weeks’ and 36.0–38.6 weeks’, and a postpartum oral glucose tolerance test (OGTT) assessment (6.0–23.6 weeks after delivery). At each visit, clinical assessment, HbA1c, and (blinded) CGM are evaluated, alongside validated patient-reported outcome questionnaires. The primary objective is to compare the incidence of a composite of adverse pregnancy outcomes between the rt-CGM and SMBG groups. The primary outcome is a composite of adverse pregnancy outcomes including preterm delivery 24 h, neonatal respiratory distress, stillbirth or neonatal death, phototherapy, birth trauma, and shoulder dystocia. Secondary outcomes include maternal glycemia, insulin use, pregnancy and neonatal outcomes, glycemic variability, patient-reported outcomes, and prespecified secondary analyses according to timing of GDM diagnosis and maternal BMI. Trial Registration: ClinicalTrials.gov: NCT06310356. First posted: 15 March 2024.
- 29 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (19) , 7581
Open AccessContinuous Glucose Monitoring for Women with Gestational Diabetes, CORDELIA: A Multicentric Randomized Controlled Trial, Methodology and Design
Background/Objectives: Gestational diabetes mellitus (GDM) is associated with increased short- and long-term risks for both mother and child. Screening and treatment between 24 and 30 weeks’ gestation reduces adverse pregnancy outcomes, while emerging evidence suggests that earlier diagnosis and treatment (<20 weeks’) in high-risk populations may further improve neonatal outcomes. Currently, self-monitoring of blood glucose (SMBG) remains the standard of care for management but provides only intermittent glycemic data and limited insight into overall glucose patterns. Real-time continuous glucose monitoring (rt-CGM) has transformed management in pregnancies complicated by type 1 diabetes but has shown conflicting results in GDM; it is thus unclear whether similar benefits may extend to women with GDM, including women with early GDM. Methods: The Continuous Glucose Monitoring for Women With Gestational Diabetes (CORDELIA) study is an ongoing, large, open-label, multicenter randomized controlled trial conducted across 14 centers in Belgium and two centers in Australia. Women diagnosed with GDM are randomized in a 1:1 ratio to either rt-CGM (intervention group) or standard care with SMBG (control group). Both women with early GDM diagnosed before 20 weeks’ gestation and those diagnosed between 24.0 and 29.6 weeks’ gestation are included. Participants attend the following visits: baseline visit at GDM diagnosis, an additional visit at 20.0–23.9 weeks’ (if early GDM), 31.0–33.6 weeks’ and 36.0–38.6 weeks’, and a postpartum oral glucose tolerance test (OGTT) assessment (6.0–23.6 weeks after delivery). At each visit, clinical assessment, HbA1c, and (blinded) CGM are evaluated, alongside validated patient-reported outcome questionnaires. The primary objective is to compare the incidence of a composite of adverse pregnancy outcomes between the rt-CGM and SMBG groups. The primary outcome is a composite of adverse pregnancy outcomes including preterm delivery 24 h, neonatal respiratory distress, stillbirth or neonatal death, phototherapy, birth trauma, and shoulder dystocia. Secondary outcomes include maternal glycemia, insulin use, pregnancy and neonatal outcomes, glycemic variability, patient-reported outcomes, and prespecified secondary analyses according to timing of GDM diagnosis and maternal BMI. Trial Registration: ClinicalTrials.gov: NCT06310356. First posted: 15 March 2024.
- Open Access
- 27 August 2026
- Published by Springer Nature in BMC Medicine
- Vol. 24 (1) , 476
Conflicting evidence for continuous glucose monitoring in gestational diabetes: current challenges and the imperative for individual participant data meta-analysis
- 27 August 2026
- Published by Springer Nature in BMC Medicine
- Vol. 24 (1) , 476
Open AccessConflicting evidence for continuous glucose monitoring in gestational diabetes: current challenges and the imperative for individual participant data meta-analysis